secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K/A
Filed at:   2023-12-26T23:59:59+00:00
Accession:  0001193125-23-302252
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 9.01, 2.01
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines issues 54.8M shares for EQRx acquisition; pro forma shows $513M net loss
--------------------------------------------------------------------------------

- Acquisition closed Nov 8, 2023; issued 54.8M shares valued at ~$1.086B based on $20.02 RVMD price.
- EQRx contributed $315.7M cash and $896.6M marketable securities; accounted as capital-raising with asset acquisition.
- Pro forma combined cash & securities = $2.01B; net loss for 9M 2023: $513M; FY2022: $443M.
- One-time transaction costs of $14M and severance of $11.8M recorded as equity reductions and accruals.
- Pro forma EPS $(3.24) for 9M 2023 and $(3.27) for FY2022, on 158.5M and 135.4M weighted shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000119312523302252/0001193125-23-302252-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000119312523302252/d613320d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-302252

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer